The earnings call reflected a positive sentiment with strong revenue growth driven by the U.S. thrombectomy business and strategic investments in new products like RUBY XL. However, challenges remain in the international segment due to China and a slower-growing stroke market.

Company Guidance

During Penumbra's Second Quarter 2025 Conference Call, the company updated its guidance for the year, reflecting strong financial performance and strategic initiatives. Total revenue for Q2 2025 was reported at $339.5 million, marking a 13.4% increase year-over-year on a reported basis and 12.7% on a constant currency basis. The U.S. thrombectomy business was a key driver, with revenue growing by 22.6% year-over-year, largely due to a 42% increase in the U.S. Venous Thromboembolism (VTE) franchise. Despite a 3.2% decline in international sales, excluding China, international thrombectomy revenue grew by 14.4%. Gross margin for the quarter was 66%, with an outlook to exceed 70% by the end of 2026. Operating expenses were at $183.2 million, or 54% of revenue, and adjusted EBITDA reached $61.4 million, representing 18.1% of total revenue. The company raised its full-year 2025 revenue guidance to between $1.355 billion and $1.370 billion, indicating 13% to 15% growth, while maintaining gross and operating margin targets.

Strong Revenue Growth

Penumbra reported total revenue of $339.5 million for the second quarter of 2025, representing a year-over-year growth of 13.4% on a reported basis and 12.7% on a constant currency basis.

U.S. Thrombectomy Business Performance

Second quarter U.S. thrombectomy revenue increased 22.6% year-over-year to $188.5 million, led by 42% year-over-year growth in the U.S. VTE franchise.

International Thrombectomy Growth

International thrombectomy business increased by 16.2%, excluding the impact of China, the growth was 14.4% year-over-year.

Improved Gross Margin

Gross margin for the second quarter of 2025 was 66%, compared to 54.4% in the second quarter of 2024, which included a one-time $33.4 million Immersive Healthcare inventory write-off.

STORM-PE Study Completion

Completed enrollment in STORM-PE, a prospective multicenter randomized controlled trial, ahead of schedule, with results expected to be presented in the fall.

Penumbra (PEN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PEN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	0.92 / -	0.85	―	―	―
Jul 29, 2025	2025 (Q2)	0.82 / 0.86	0.64	34.37% (+0.22)	―
Apr 23, 2025	2025 (Q1)	0.67 / 0.83	0.41	102.44% (+0.42)	―
Feb 18, 2025	2024 (Q4)	0.90 / 0.97	0.76	27.63% (+0.21)	―
Oct 30, 2024	2024 (Q3)	0.69 / 0.85	0.67	26.87% (+0.18)	―
Jul 30, 2024	2024 (Q2)	0.56 / 0.64	0.43	48.84% (+0.21)	―
May 07, 2024	2024 (Q1)	0.39 / 0.41	0.23	78.26% (+0.18)	―
Feb 22, 2024	2023 (Q4)	0.70 / 0.76	0.16	375.00% (+0.60)	―
Nov 02, 2023	2023 (Q3)	0.45 / 0.67	0.01	6600.00% (+0.66)	―
Aug 01, 2023	2023 (Q2)	0.28 / 0.43	0.01	4200.00% (+0.42)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PEN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 29, 2025	$227.15	$254.21	+11.91%
Apr 23, 2025	$278.77	$298.25	+6.99%
Feb 18, 2025	$271.14	$303.76	+12.03%
Oct 30, 2024	$211.29	$228.87	+8.32%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Penumbra Inc. (PEN) report earnings?

Penumbra Inc. (PEN) is schdueled to report earning on Oct 29, 2025, After Close (Confirmed).

What is Penumbra Inc. (PEN) earnings time?

Penumbra Inc. (PEN) earnings time is at Oct 29, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PEN EPS forecast?

PEN EPS forecast for the fiscal quarter 2025 (Q3) is 0.92.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing